October 16, 2015 12:24am

 

Strength in small caps and the stem, cell and gene therapy RegMed sector is a great sign!

Stocks piled on big gains Thursday, as the NASDAQ confidently retook its 50-day moving average. Subscription required: http://www.regmedinvestors.com/user/register

 

Make RegMed Investors your daily destination. We’ve gathered and sifted through news and share pricing data you need in one convenient spot.

 

 

The NASDAQ plowed ahead 1.8%, while the S&P 500 added 1.5% and the Dow added 1.3%. The IBD 50 popped 1.7%. Volume rose across the board. The small-cap Russell 2000 was the day's star, thrusting 2.3%.

The NASDAQ closed UP +87.25 or +1.82% to 4,870.10 and the DOW closed UP +217.00 or +1.28% to 17,141.75.

 

 

Henry’omics:

  • The stem, cell, gene therapy and regenerative medicine (SCGT&RM) sector opened to the upside – finally and maintained until the close!
  • Bada Bing, we accomplish a big thing – a solid upside!

The NASDAQ outperformed, closing up 1.8% as:

  • The iShares Biotechnology Stocks ETF (IBB) leaped nearly 4.4% having closed UP +2.82 or +0.94% on Wednesday after Tuesday’s decline of -9.78 or -3.17% after Monday eked out a gain of 0.03%;
  • The NASDAQ Biotechnology index (NBI) closed UP +138.63 or +4.39% on Thursday following Wednesday’s advance of +27.72 or +0.89% after Tuesday’s decline of -104.09 or -3.22% following Monday’s advance of +1.99 or +0.06% on Monday;
  • The Russell 2000 (IWM) closed UP on Thursday +2.70 or +2.39% following Wednesday’s decline of -1.12 or -0.98% after Tuesday’s decline of -1.60 or -1.38% following Monday’s decline of -0.17 or -0.15%;
  • The SPDR SD&P Biotech ETF (XBI) closed UP +4.49 or +7.26% following Wednesday’s advance of +0.69 or +1.13% after Tuesday’s decline of -2.80 or 4.38% following Monday’s decline of -0.79 or -1.22%

 

 

A day in the life of the stem, cell and gene therapy RegMed (SCGT & RM) sector:

  • SCGT & RM equities opened positive with an Advance/Decline line (A/DL) of 26/5 and 2 flats and closed with a positive A/DL of 37/1 and 5 flat;
  • Volume was  moderate to high!
  • My fear gauge of fear - the CBOE Volatility Index (VIX) traded Thursday near 16 following Wednesday’s below 18 following Tuesday’s above 17.5 after Monday’s above 15.

 

 

Dosing the sector – 43 Patients:

  • Open: POSITIVE with 5 decliners, 26 advancers and 2 flats;
  • Closing bell: POSITIVE with 1 decliner, 37 advancers and 5 flat

 

 

Thursday’s trading indications: 9 hit/ 1 miss:

  • Applied Genetic Technologies (AGTC) closed UP – hit;
  • Asterias (NYSEMKT: AST) closed UP – hit;
  • Bellicum (BLCM) closed UP –hit;
  • Capricor (CAPR) closed UP - miss;
  • Fate Therapeutics (FATE) closed UP -hit;
  • Harvard Apparatus RM (HART) closed UP – hit;
  • Intrexon (XON) closed UP – hit;
  • MiMedx (MDXG) closed UP – hit;
  • Osiris (OSIR) closed UP – hit;
  • Spark Therapeutics (ONCE) closed UP - hit;

 

 

Who was UP – highest 5:

  • Bluebird bio (BLUE) closed +$4.87 to $85.83;
  • Juno Therapeutics (JUNO) +$4.44 to $50.83;
  • Kite Pharma (KITE) +$4.00 to $64.40;
  • Cellectis ADR (CLLS) +$1.84 to $25.92;
  • Spark Therapeutics (ONCE) closed up +$1.60 to $52.50;

 

 

Who was down?

  • Cesca therapeutics (KOOL) closed down -$0.0029 to $0.61

 

 

Who was flat?

  • BioLife Solutions (BLFS) at $2.19;
  • Neuralstem (CUR) at $1.28;
  • ReNeuron (RENE.L) at $4.10;
  • VistaGen (VSTA) at $7.50

 

 

All investments are subject to risks. Investors should consider investment objectives. The information included above as well as individual companies and/or securities mentioned should only construed as an indication from any RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.